Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 4,410,000 shares, a growth of 14.5% from the November 15th total of 3,850,000 shares. Based on an average trading volume of 3,430,000 shares, the short-interest ratio is currently 1.3 days.
Capricor Therapeutics Trading Up 4.7 %
NASDAQ:CAPR traded up $0.62 during mid-day trading on Monday, hitting $13.88. The company had a trading volume of 1,231,417 shares, compared to its average volume of 1,182,941. Capricor Therapeutics has a 1 year low of $3.52 and a 1 year high of $23.40. The firm has a market capitalization of $631.12 million, a price-to-earnings ratio of -13.09 and a beta of 3.98. The business has a fifty day simple moving average of $18.33 and a 200-day simple moving average of $10.13.
Wall Street Analyst Weigh In
A number of research analysts have recently weighed in on the company. HC Wainwright restated a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Maxim Group increased their price target on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 25th. Oppenheimer restated an "outperform" rating and set a $15.00 price objective on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald boosted their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th. Finally, Piper Sandler initiated coverage on Capricor Therapeutics in a research report on Monday, October 21st. They set an "overweight" rating and a $35.00 price objective for the company. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $34.50.
Read Our Latest Analysis on Capricor Therapeutics
Insiders Place Their Bets
In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of Capricor Therapeutics stock in a transaction dated Friday, September 20th. The stock was acquired at an average price of $5.36 per share, for a total transaction of $14,999,997.52. Following the transaction, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. This represents a 65.21 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 12.00% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Capricor Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of CAPR. Vanguard Group Inc. boosted its stake in shares of Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company's stock valued at $9,274,000 after purchasing an additional 200,499 shares during the period. State Street Corp lifted its holdings in Capricor Therapeutics by 27.8% in the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company's stock worth $7,792,000 after buying an additional 111,291 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in Capricor Therapeutics in the 3rd quarter valued at about $3,806,000. PFM Health Sciences LP acquired a new stake in shares of Capricor Therapeutics during the third quarter valued at about $2,324,000. Finally, Renaissance Technologies LLC increased its position in shares of Capricor Therapeutics by 158.7% during the second quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company's stock worth $656,000 after acquiring an additional 84,350 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company's stock.
Capricor Therapeutics Company Profile
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
